Manesh Patel, MD

A panel of expert cardiologists share their concluding thoughts on management of polyvascular disease in clinical practice.

Cardiologists share unmet needs and emerging approaches to management of patients with polyvascular disease.

Manesh Patel, MD, reviews VOYAGER trial data and expert cardiologists share where they use DPI [dual pathway inhibition] in their practices.

Expert cardiologists discuss data from COMPASS trial and the role of rivaroxaban and low-dose aspirin in treatment of patients with CAD and PAD.

Sahil Parikh, MD, shares how lack of access to or awareness of DPI [dual pathway inhibition] causes many practices and health care providers to face a challenge in treating CAD [coronary artery disease].

Drs Patel and Bhatt discuss importance of correct dosing of direct oral anticoagulants in treatment of cardiovascular diseases.

Expert cardiologists provide an overview of dual pathway inhibition, modulation of thrombotic risk and treatment of CAD.

Dr Amy Pollak shares her thoughts on risk-benefit analysis when evaluating patients with high thrombotic/bleeding risk and treatment selection.

Dr Eric Secemsky discusses how use of stents has evolved over the years in treatment of polyvascular disease.

Dr Manesh Patel and other experts discuss the role of dual antiplatelet therapy (DAPT) in treatment of coronary artery disease.

Drs Marc Bonaca and Deepak Bhatt discuss the role of therapy intensification when managing high-risk patients with polyvascular disease.

Expert cardiologists discuss CAD guidelines and approaches to management of patients with polyvascular disease.

Dr Sahil Parikh and other experts discuss engagement of cardiologists in patients diagnosed with polyvascular disease and challenges in screening patients.

Dr Amy Pollak and other experts discuss their recommendations for screening for CAD and PAD in asymptomatic patients.

Drs Marc Bonaca and Manesh Patel provide an overview of Polyvascular Disease and prevalence of coronary artery disease and peripheral artery disease.

Final thoughts from expert KOLs regarding treatment decisions and how they relate to patient accessibility when manage dyslipidemia.

Importance of shared decision making and value-based care when making treatment decisions for cardiovascular patients.

Bempedoic acid monotherapy and its combination with ezetimibe for lipid lowering in patients intolerant to statins.

Role of dietary and lifestyle modifications as part of lipid management.

Dean Karalis, MD, provides expertise on the appropriate use of statins based on primary and secondary prevention.

Expert cardiologists express support for the uptake in the use of inclisiran once approved based on the cost-effectiveness.

Norman Lepor, MD, FACC, FAHA, FSCAI, challenges the use of ezetimibe before a PCSK9 inhibitor in a population with no acute coronary syndrome.

Key opinion leaders in cardiology share their perspectives on using inclisiran post FDA approval within the current treatment landscape based on guidelines.

Norman Lepor, MD, FACC, FAHA, FSCAI, reviews the efficacy of inclisiran in terms of LDL reduction based on the pooled analysis of the phase 3 ORION trials.

Experts review in detail the emerging use of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.

Panel of experts discuss the use and safety profile of purified icosapent ethyl compound (EPA) in prevention of CV risk.

Cardiologists briefly review the outcomes data and practical implications of novel treatment options for hyperlipidemia.

Manesh Patel, MD, briefly addresses the mechanism of action of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.

Dean Karalis, MD, provides his perspective on intensive LDL lowering in patients with risk for high cholesterol and related disorders.

Linda Hemphill, MD, shares her views on how familial hypercholesterolemia impacts the assessment of high-risk patients.